vs
Side-by-side financial comparison of Oak Valley Bancorp (OVLY) and REGENXBIO Inc. (RGNX). Click either name above to swap in a different company.
REGENXBIO Inc. is the larger business by last-quarter revenue ($30.3M vs $21.3M, roughly 1.4× Oak Valley Bancorp). Oak Valley Bancorp runs the higher net margin — 29.8% vs -221.3%, a 251.1% gap on every dollar of revenue. On growth, REGENXBIO Inc. posted the faster year-over-year revenue change (43.0% vs 10.4%). Oak Valley Bancorp produced more free cash flow last quarter ($24.6M vs $-52.8M). Over the past eight quarters, REGENXBIO Inc.'s revenue compounded faster (39.4% CAGR vs 6.5%).
Valley National Bancorp, doing business as Valley Bank, is a regional bank holding company headquartered in Morristown, New Jersey, with approximately $64 billion in assets. Its principal subsidiary, Valley National Bank, currently operates over 230 branch locations and commercial banking offices across New Jersey, New York, Florida, Alabama, California, and Illinois. Valley Bank is one of the largest commercial banks headquartered in New Jersey.
REGENXBIO Inc. is a clinical-stage biotechnology firm focused on gene therapy for rare severe genetic diseases. It licenses its proprietary AAV vector technology to global biopharma partners, and advances its own pipeline targeting ophthalmology, metabolic and neurodegenerative disorders.
OVLY vs RGNX — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $21.3M | $30.3M |
| Net Profit | $6.3M | $-67.1M |
| Gross Margin | — | — |
| Operating Margin | 38.3% | -190.0% |
| Net Margin | 29.8% | -221.3% |
| Revenue YoY | 10.4% | 43.0% |
| Net Profit YoY | 5.4% | -31.2% |
| EPS (diluted) | $0.76 | $-1.30 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $21.3M | $30.3M | ||
| Q3 25 | $21.2M | $29.7M | ||
| Q2 25 | $19.9M | $21.4M | ||
| Q1 25 | $19.4M | $89.0M | ||
| Q4 24 | $19.3M | $21.2M | ||
| Q3 24 | $19.5M | $24.2M | ||
| Q2 24 | $19.1M | $22.3M | ||
| Q1 24 | $18.8M | $15.6M |
| Q4 25 | $6.3M | $-67.1M | ||
| Q3 25 | $6.7M | $-61.9M | ||
| Q2 25 | $5.6M | $-70.9M | ||
| Q1 25 | $5.3M | $6.1M | ||
| Q4 24 | $6.0M | $-51.2M | ||
| Q3 24 | $7.3M | $-59.6M | ||
| Q2 24 | $5.9M | $-53.0M | ||
| Q1 24 | $5.7M | $-63.3M |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | 70.2% | ||
| Q3 24 | — | 48.8% | ||
| Q2 24 | — | 52.5% | ||
| Q1 24 | — | 72.6% |
| Q4 25 | 38.3% | -190.0% | ||
| Q3 25 | 40.3% | -176.3% | ||
| Q2 25 | 36.1% | -296.3% | ||
| Q1 25 | 35.0% | 13.6% | ||
| Q4 24 | 40.1% | -242.1% | ||
| Q3 24 | 50.2% | -256.6% | ||
| Q2 24 | 39.0% | -251.3% | ||
| Q1 24 | 38.5% | -408.8% |
| Q4 25 | 29.8% | -221.3% | ||
| Q3 25 | 31.6% | -208.3% | ||
| Q2 25 | 28.1% | -331.8% | ||
| Q1 25 | 27.3% | 6.8% | ||
| Q4 24 | 31.2% | -241.3% | ||
| Q3 24 | 37.6% | -246.3% | ||
| Q2 24 | 30.9% | -237.7% | ||
| Q1 24 | 30.5% | -405.4% |
| Q4 25 | $0.76 | $-1.30 | ||
| Q3 25 | $0.81 | $-1.20 | ||
| Q2 25 | $0.67 | $-1.38 | ||
| Q1 25 | $0.64 | $0.12 | ||
| Q4 24 | $0.73 | $-0.99 | ||
| Q3 24 | $0.89 | $-1.17 | ||
| Q2 24 | $0.71 | $-1.05 | ||
| Q1 24 | $0.69 | $-1.38 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $232.2M | $230.1M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $208.0M | $102.7M |
| Total Assets | $2.0B | $453.0M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $232.2M | $230.1M | ||
| Q3 25 | $247.2M | $274.2M | ||
| Q2 25 | $198.9M | $323.3M | ||
| Q1 25 | $209.3M | $267.9M | ||
| Q4 24 | $168.8M | $234.7M | ||
| Q3 24 | $213.9M | $255.5M | ||
| Q2 24 | $180.3M | $290.4M | ||
| Q1 24 | $169.7M | $338.7M |
| Q4 25 | $208.0M | $102.7M | ||
| Q3 25 | $198.3M | $161.5M | ||
| Q2 25 | $185.8M | $213.7M | ||
| Q1 25 | $183.5M | $274.2M | ||
| Q4 24 | $183.4M | $259.7M | ||
| Q3 24 | $185.4M | $301.4M | ||
| Q2 24 | $171.8M | $348.3M | ||
| Q1 24 | $166.9M | $390.7M |
| Q4 25 | $2.0B | $453.0M | ||
| Q3 25 | $2.0B | $525.2M | ||
| Q2 25 | $1.9B | $581.0M | ||
| Q1 25 | $1.9B | $490.9M | ||
| Q4 24 | $1.9B | $466.0M | ||
| Q3 24 | $1.9B | $519.1M | ||
| Q2 24 | $1.8B | $569.4M | ||
| Q1 24 | $1.8B | $629.2M |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $28.7M | $-52.3M |
| Free Cash FlowOCF − Capex | $24.6M | $-52.8M |
| FCF MarginFCF / Revenue | 115.4% | -174.0% |
| Capex IntensityCapex / Revenue | 19.3% | 1.7% |
| Cash ConversionOCF / Net Profit | 4.53× | — |
| TTM Free Cash FlowTrailing 4 quarters | $41.7M | $-126.4M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $28.7M | $-52.3M | ||
| Q3 25 | $7.1M | $-56.0M | ||
| Q2 25 | $5.6M | $-49.3M | ||
| Q1 25 | $8.0M | $33.6M | ||
| Q4 24 | $25.6M | $-31.6M | ||
| Q3 24 | $8.9M | $-40.5M | ||
| Q2 24 | $4.2M | $-45.5M | ||
| Q1 24 | $8.3M | $-55.5M |
| Q4 25 | $24.6M | $-52.8M | ||
| Q3 25 | $6.3M | $-56.5M | ||
| Q2 25 | $4.0M | $-49.7M | ||
| Q1 25 | $6.8M | $32.6M | ||
| Q4 24 | $23.9M | $-32.7M | ||
| Q3 24 | $8.7M | $-40.9M | ||
| Q2 24 | $3.6M | $-46.0M | ||
| Q1 24 | $8.1M | $-56.0M |
| Q4 25 | 115.4% | -174.0% | ||
| Q3 25 | 30.0% | -189.9% | ||
| Q2 25 | 20.1% | -232.8% | ||
| Q1 25 | 35.0% | 36.6% | ||
| Q4 24 | 123.8% | -154.2% | ||
| Q3 24 | 44.9% | -168.9% | ||
| Q2 24 | 18.8% | -206.2% | ||
| Q1 24 | 43.4% | -358.5% |
| Q4 25 | 19.3% | 1.7% | ||
| Q3 25 | 3.7% | 1.7% | ||
| Q2 25 | 8.0% | 1.8% | ||
| Q1 25 | 6.1% | 1.2% | ||
| Q4 24 | 9.2% | 5.1% | ||
| Q3 24 | 0.9% | 1.3% | ||
| Q2 24 | 3.1% | 2.1% | ||
| Q1 24 | 0.7% | 3.6% |
| Q4 25 | 4.53× | — | ||
| Q3 25 | 1.07× | — | ||
| Q2 25 | 1.00× | — | ||
| Q1 25 | 1.50× | 5.53× | ||
| Q4 24 | 4.27× | — | ||
| Q3 24 | 1.22× | — | ||
| Q2 24 | 0.71× | — | ||
| Q1 24 | 1.45× | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
OVLY
Segment breakdown not available.
RGNX
| Novartis Gene Therapies | $24.2M | 80% |
| Nippon Shinyaku Collaboration And License Agreement | $4.3M | 14% |
| Nippon Shinyaku Services | $1.4M | 5% |
